Cho Sungsin, Joh Jin Hyun
Department of Surgery, Kyung Hee University Hospital at Gangdong, Seoul 05278, Republic of Korea.
J Clin Med. 2025 Jul 25;14(15):5277. doi: 10.3390/jcm14155277.
: There are no reports about the nationwide trends in abdominal aortic aneurysm (AAA) repair and mortality rates. This study aims to evaluate the trend in AAA treatment and related mortality, including ruptured AAAs (rAAAs) and intact AAAs (iAAAs) over the last 13 years. : This serial, cross-sectional study investigated the time trends in patients who were treated for an AAA and underwent an aneurysm repair between 2010 and 2022. Data from the Health Insurance Review and Assessment Service (HIRA) and Statistics Korea were used. A linear-by-linear association and Poisson regression analysis were performed to determine the changes in the treatment of AAAs and related mortality. : The number of patients with an rAAA increased from 462 in 2010 to 770 in 2022 (relative risk, RR 1.57; < 0.0001). The number of patients with an iAAA increased from 3685 to 12,399 in the same period (RR 3.16; < 0.0001). Endovascular aneurysm repair (EVAR) has been more commonly performed since 2011. During the study period, EVAR increased from 406 to 1161 (RR 2.68; < 0.0001). Although the annual mortality rates after iAAA treatment decreased from 1.4% to 0.7% (mean mortality rate, 1.1%), the mortality rates after rAAA treatment were similar, ranging from 34.6% to 34.2%, during the study period (mean mortality rate, 35.2%). : During the last 13 years, the annual number of patients with rAAAs and iAAAs has increased. Since 2011, EVAR has been more commonly performed. The annual iAAA-related mortality rate decreased along with the increasing trend in EVAR. However, the annual rAAA-related mortality rate did not change.
目前尚无关于腹主动脉瘤（AAA）修复及死亡率全国趋势的报告。本研究旨在评估过去13年中AAA治疗及相关死亡率的趋势，包括破裂性腹主动脉瘤（rAAA）和未破裂腹主动脉瘤（iAAA）。 ：本系列横断面研究调查了2010年至2022年间接受AAA治疗并进行动脉瘤修复的患者的时间趋势。使用了健康保险审查和评估服务（HIRA）及韩国统计局的数据。进行线性-线性关联分析和泊松回归分析以确定AAA治疗及相关死亡率的变化。 ：rAAA患者数量从2010年的462例增加至2022年的770例（相对风险，RR 1.57；<0.0001）。同期iAAA患者数量从3685例增加至12399例（RR 3.16；<0.0001）。自2011年以来，血管内动脉瘤修复术（EVAR）的应用更为普遍。在研究期间，EVAR从406例增加至1161例（RR 2.68；<0.0001）。尽管iAAA治疗后的年死亡率从1.4%降至0.7%（平均死亡率为1.1%），但在研究期间rAAA治疗后的死亡率相似，在34.6%至34.2%之间（平均死亡率为35.2%）。 ：在过去13年中，rAAA和iAAA的年患者数量均有所增加。自2011年以来，EVAR的应用更为普遍。iAAA相关的年死亡率随EVAR应用增加的趋势而下降。然而，rAAA相关的年死亡率未发生变化。
